The next era of cancer is long-term prevention drugs
Billions have been invested in cancer research, unlocking deep insights into the molecular, immune system, and lifestyle factors that predispose us to cancer. These insights shouldn’t just be used to treat cancer after it appears—they should be extrapolated and exploited to prevent its onset altogether.
We already have proof points that cancer prevention is not only possible, but powerfully effective:
The most successful cancer vaccines to date are actually viral vaccines—targeting viruses like HPV and HBV that can trigger downstream cancer. While there are therapeutic cancer vaccines in development, they are generally used after diagnosis, not before.
The next frontier is deliberate, long-term chemoprevention and immunoprevention: safe, scalable drugs or interventions designed to reduce lifetime cancer risk by acting on the known mechanisms of cancer initiation—DNA instability, chronic inflammation, immune evasion, epigenetic drift, and viral persistence.
This opens new therapeutic classes such as:
The market case is massive. Preventing a single case of cancer—especially when detected at a late stage—saves hundreds of thousands in direct costs and millions in quality-adjusted life years. A new class of cancer prevention drugs could redefine oncology from a reactive, late-stage discipline to a proactive, lifespan-oriented one.
